I-Mab expected to post a loss of 22 cents a share - Earnings Preview

NovaBridge Biosciences

13/08/2024 18:05

* I-Mab  IMAB.OQ   IMAB.O  is expected to report resultson
August
15 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for I-Mab is for a loss
of 22
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for I-Mab is
$7.00​,
above​ its last closing price of $1.06. ​​​

This summary was machine generated August 13 at 17:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)